CDK4/6 Inhibitors: One Class, Three Outcomes

Anmeldung erfolgt in Kürze...

query
ai

Details werden geladen...

https://www.medscape.com/c99/p10/cdk4-6-inhibitors-breast-cancer-one-drug-class-three-2026a1000y16

CDK4/6 Inhibitors: One Class, Three Outcomes

Abemaciclib and ribociclib now show adjuvant survival benefit; palbociclib didn't. Laura Spring, MD, on picking the right agent per patient.

Ähnliche Seiten

TKI Discontinuation Feasible After ALL Treatment

https://www.medscape.com/viewarticle/tki-discontinuation-feasible-after-acute-lymphoblastic-2026a1000xvt